SEC Form 4 · accession 0001209191-15-023110
Tracon Pharmaceuticals, Inc. · TCON
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Martin A Mattingly
Director
Period of report
Mar 4, 2015
Accepted (ET)
Mar 5, 2015 · 6:07 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001394319
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option ( Right to Buy)F1 | $16.38 | Mar 4, 2015 | A | 15,483 | A | — | Mar 3, 2025 | Common Stock | 15,483 | 15,483 | D |
Explanation of responses
- F1The shares subject to the option shall vest and become exercisable in three equal annual installments commencing on the first anniversary of the grant date set forth in column 3 above.